275 related articles for article (PubMed ID: 19527806)
1. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
Mancini T; Mazziotti G; Doga M; Carpinteri R; Simetovic N; Vescovi PP; Giustina A
Bone; 2009 Oct; 45(4):784-8. PubMed ID: 19527806
[TBL] [Abstract][Full Text] [Related]
2. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density is not sensitive enough to assess the risk of vertebral fractures in type 2 diabetic women.
Yamamoto M; Yamaguchi T; Yamauchi M; Kaji H; Sugimoto T
Calcif Tissue Int; 2007 Jun; 80(6):353-8. PubMed ID: 17549536
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G;
Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031
[TBL] [Abstract][Full Text] [Related]
5. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
[TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes.
Iliadis F; Kadoglou NP; Hatzitolios A; Karamouzis M; Alevizos M; Karamitsos D
In Vivo; 2007; 21(6):1107-14. PubMed ID: 18210765
[TBL] [Abstract][Full Text] [Related]
9. Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes.
Yamaguchi T; Kanazawa I; Yamamoto M; Kurioka S; Yamauchi M; Yano S; Sugimoto T
Bone; 2009 Aug; 45(2):174-9. PubMed ID: 19446053
[TBL] [Abstract][Full Text] [Related]
10. Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats.
Morsy MA; Ashour OM; Fouad AA; Abdel-Gaber SA
Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):173-7. PubMed ID: 19566821
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.
Kadoglou NP; Iliadis F; Angelopoulou N; Perrea D; Liapis CD; Alevizos M
Diabet Med; 2008 Mar; 25(3):333-40. PubMed ID: 18307460
[TBL] [Abstract][Full Text] [Related]
12. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.
Vinik AI; Zhang Q
Diabetes Care; 2007 Apr; 30(4):795-800. PubMed ID: 17259481
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the relationship between type 2 diabetes and osteoporosis using Bayesian inference.
Sta Romana M; Li-Yu JT
J Clin Densitom; 2007; 10(4):386-90. PubMed ID: 17993401
[TBL] [Abstract][Full Text] [Related]
14. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.
Kiyici S; Ersoy C; Kaderli A; Fazlioglu M; Budak F; Duran C; Gul OO; Sigirli D; Baran I; Tuncel E; Erturk E; Imamoglu S
Diabetes Res Clin Pract; 2009 Oct; 86(1):44-50. PubMed ID: 19674806
[TBL] [Abstract][Full Text] [Related]
15. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
[TBL] [Abstract][Full Text] [Related]
16. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications.
Yamamoto M; Yamaguchi T; Yamauchi M; Kaji H; Sugimoto T
J Bone Miner Res; 2009 Apr; 24(4):702-9. PubMed ID: 19049338
[TBL] [Abstract][Full Text] [Related]
17. Distal upper and lower limb fractures associated with thiazolidinedione use.
Jones SG; Momin SR; Good MW; Shea TK; Patric K
Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
[TBL] [Abstract][Full Text] [Related]
18. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
19. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
[TBL] [Abstract][Full Text] [Related]
20. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]